Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.33% to £18.37 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.65% to ...

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

This might drive the stock higher in the near term. Hikma Pharmaceuticals ( LON:HIK ) First Half 2024 Results Key Financial Results Revenue: US$1.57b (up 10.0% from 1H... Shares of Hikma ...

Hikma Pharmaceuticals Usa Inc was founded in 2011 and operates in Eatontown, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.

Hikma Pharmaceuticals (GB:HIK) has released an update. Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive ...

Hikma Pharmaceuticals is expanding its market ... and efficiently propel revenue expansion. Competitive Strategy: This report crafts a strong competitive strategy tailored to the hybrid medicine ...

Ionis Pharmaceuticals exceeded revenue estimates by 3.4%, reporting $134 million against a $129.57 million expectation. Spinraza royalties decreased by $10 million year over year to $57 million ...

Get a Sample Copy of This Report @ The report sheds light on the competitive landscape, segmentation, geographical expansion, revenue, production, and consumption growth of the Saudi Arabia ...

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals reported significant growth in the third quarter of 2024, with total revenue surging by 71% to $10.4 million, driven ...